Acalabrutinib (Calquence; AstraZeneca) demonstrated a more modest ORR of 40% in a smaller 25-patient cohort, with median progression-free survival (PFS) of 3.2 months. While less robust than ...
The Gene Synthesis Market has emerged as one of the most transformative segments within modern biotechnology, driven by rapid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results